This is the official page for Vast Therapeutics.
Vast is a preclinical biotechnology company focused on treating the world’s most challenging drug-resistant microbial infections that represent one of the greatest threats to global health, food security, and economic development.
Vast’s patented technology gives us the unique ability to harness the unmatched antimicrobial activity of nitric oxide. This endogenously produced reactive compound plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.
This technology redefines broad-spectrum antimicrobial capability with demonstrated in vitro activity and high potency against a wide range of infectious bacteria and viruses, including inhibiting viral replications of SARS-CoV-2, the human coronavirus that causes COVID-19.
Vast is a preclinical biotechnology company focused on treating the world’s most challenging drug-resistant microbial infections that represent one of the greatest threats to global health, food security, and economic development.
Vast’s patented technology gives us the unique ability to harness the unmatched antimicrobial activity of nitric oxide. This endogenously produced reactive compound plays a vital role in the natural immune system response to microbial pathogens. Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.
This technology redefines broad-spectrum antimicrobial capability with demonstrated in vitro activity and high potency against a wide range of infectious bacteria and viruses, including inhibiting viral replications of SARS-CoV-2, the human coronavirus that causes COVID-19.
Employees: 11-50
Total raised: $2M
Founded date: 2017
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.09.2025 | Grant | $2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 16.09.2025 | Vast Therapeutics Awarded Another $2 Million Grant to Combat Rare Respiratory Disease | Funds from NIH will Advance Orphan Drug Development as a Potential Treatment for Non-tuberculous Mycobacteria Pulmonary Disease Our approach is unlike any treatment strategy currently prescribed by clinicians to treat NTM- PD” — Dr. Nathan ... |
| 16.07.2025 | Vast’s Lead Drug Candidate Receives Orphan Drug Designation for Treatment of Respiratory Infection for Cystic Fibrosis | Phase 1 program set to begin Q4 2025 in the US Orphan drug designation marks an important milestone in our mission to address critical challenges in lung health” — Paul Bruinenberg MD MBA, Chief Medical Officer of Vast TherapeuticsMORRISVIL... |
| 15.05.2019 | KNOW Bio Closes $30M Financing | KNOW Bio, LLC, (the Company or KNOW Bio), an RTP based conglomerate of biotechnology and MedTech companies, announced today that the Company has completed its next round of financing with a single investor, Reedy Creek Investments, LLC (Ree... |
| 15.05.2019 | KNOW Bio Closes $30M Financing | KNOW Bio, LLC, (the Company or KNOW Bio), an RTP based conglomerate of biotechnology and MedTech companies, announced today that the Company has completed its next round of financing with a single investor, Reedy Creek Investments, LLC (Ree... |
| 05.12.2018 | Vast Therapeutics Closes Series A Funding | Vast Therapeutics, Inc., a Durham, N.C.-based preclinical-stage pharmaceutical company, completed a Series A financing of undisclosed amount. Shionogi & Co. was the single investor in the round. The company intends to use the funds to a... |